The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency

Todd W.B. Gehr, David W. Rudy, Gary R. Matzke, William G. Kramer, Domenic A. Sica, D. Craig Brater

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Torsemide is a diuretic that acts in the thick ascending limb of the loop of Henle. Unlike furosemide, it undergoes substantial hepatic elimination and should not accumulate in patients with renal insufficiency. Therefore the pharmacokinetics of intravenous and oral torsemide and its metabolites were investigated in patients with chronic renal insufficiency. Two groups of 24 patients stratified by creatinine clearance (30 to 60 ml/min and <30 ml/min) were studied in two separate randomized dose escalating crossover studies, one using intravenous torsemide and the other using oral torsemide. The pharmacokinetics of both intravenous and oral torsemide were linear over the dosage range studied. Absolute bioavailability was essentially 100%. Renal clearance was greatly diminished and correlated with renal function. Total plasma clearance and half‐life were not related to renal function and were found to be similar to those of healthy subjects. The substantial nonrenal clearance of torsemide prevents accumulation in patients with chronic renal insufficiency. Clinical Pharmacology and Therapeutics (1994) 56, 31–38; doi:

Original languageEnglish
Pages (from-to)31-38
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume56
Issue number1
DOIs
StatePublished - Jul 1994

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency'. Together they form a unique fingerprint.

Cite this